Cosmetically disabling persistent sequelae ≥ 6 months after randomisation Clinical assessment · Bell's palsy
Corticosteroids showed no clear difference in cosmetically disabling persistent sequelae ≥ 6 months after… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Motor synkinesis or crocodile tears Clinical assessment · Bell's palsy
Corticosteroids probably leads to lower motor synkinesis and crocodile tears Clinical assessment compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Adverse effects · Bell's palsy
Corticosteroids showed no clear difference in adverse effects compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in average muscle score: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
4‐stair climbing time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Weight gain · patients with Duchenne muscular dystrophy
1 finding from 1 review
Behavioural changes ‐ prednisone (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
Corticosteroids showed no clear difference in behavioural changes ‐ prednisone (0.75 mg/kg/day) compared with placebo (moderate certainty).
1 finding from 1 review
Fracture · patients with Duchenne muscular dystrophy
1 finding from 1 review
Improvement in sensory nerve function at 1 year · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in improvement in sensory nerve function at 1 year Defined as a… compared with placebo (moderate certainty).
1 finding from 1 review
Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in participation at 1 year ‐ not reported · people with nerve damage (6 to 24 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects requiring withdrawal/discontinuation of study medication · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as adverse events requiring withdrawal of… compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in nerve pain and in nerve tenderness at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in activities of daily living at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limitations in participation at 1 year ‐ not reported · people with nerve damage (< 6 months' duration) in leprosy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).
1 finding from 1 review